These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38557295)

  • 1. Real-world effectiveness of long-acting injectable vs. oral antipsychotics in patients with bipolar I disorder: a 1-year retrospective observational study.
    Korkmaz ŞA; Gürler S
    Curr Med Res Opin; 2024 May; 40(5):855-861. PubMed ID: 38557295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
    Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
    J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: A 1-year retrospective cohort study.
    Chan HW; Huang CY; Feng WJ; Yen YC
    J Affect Disord; 2016 Nov; 205():360-364. PubMed ID: 27568173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-acting injectable antipsychotics on emergency department visits and hospital admissions in people with bipolar disorder: A retrospective mirror-image analysis from the Northern Milan Area Cohort (NOMIAC) study.
    Bartoli F; Bachi B; Calabrese A; Cioni RM; Guzzi P; Nasti C; Palpella D; Barbieri FF; Limonta S; Crocamo C; Carrà G
    J Affect Disord; 2022 Dec; 318():88-93. PubMed ID: 36058358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
    Lin CH; Chan HY; Hsu CC; Chen FC
    J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics.
    Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
    Clin Drug Investig; 2021 Jan; 41(1):99-113. PubMed ID: 33331979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
    CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder.
    Wu CS; Hsieh MH; Tang CH; Chang CJ
    J Affect Disord; 2016 Jun; 197():189-95. PubMed ID: 26994437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
    Kishi T; Citrome L; Sakuma K; Iwata N
    Psychiatry Res; 2024 Mar; 333():115761. PubMed ID: 38301289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.
    Schoretsanitis G; Kane JM; Correll CU; Rubio JM
    Schizophr Bull; 2022 Mar; 48(2):296-306. PubMed ID: 34355232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder.
    Abdel-Baki A; Thibault D; Medrano S; Stip E; Ladouceur M; Tahir R; Potvin S
    Early Interv Psychiatry; 2020 Feb; 14(1):69-79. PubMed ID: 31125513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
    Pacchiarotti I; Tiihonen J; Kotzalidis GD; Verdolini N; Murru A; Goikolea JM; Valentí M; Aedo A; Vieta E
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):457-470. PubMed ID: 30770235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
    Yan T; Greene M; Chang E; Touya M; Broder MS
    J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.